Trial Profile
A Phase 1 Open-label Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of HBI-8000 in Japanese Patients With Non Hodgkin's Lymphoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Oct 2022
Price :
$35
*
At a glance
- Drugs Tucidinostat (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Sponsors HUYA Bioscience International
- 18 Sep 2022 Preliminary results assessing safety and efficacy published in the Japanese Journal of Clinical Oncology
- 10 Jan 2017 Status changed from active, no longer recruiting to completed.
- 06 Dec 2016 Preliminary results assessing the efficacy, safety and maximum tolerated dose (MTD) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.